Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer (2013)

Peer-Reviewed Study · Nygren P; Fryknas M; Agerup B; Larsson R · October 18, 2013

Nygren P et al., 2013-10-18: A 1,600-compound screen in colon cancer lines that identified the benzimidazoles as a hit cluster and showed mebendazole's activity across 80% of colon cancer lines in the NCI-60 panel, with kinase interactions that albendazole lacked. It broadened the mebendazole-cancer case beyond lung and brain.

Analysis of chemical similarity of the hit compounds revealed several distinct clusters, among them the antiparasitic benzimidazole group. Two of these compounds, mebendazole (MBZ) and albendazole (ABZ) are registered for human use.

abstract

Nygren P et al., 2013-10-18: A 1,600-compound screen in colon cancer lines that identified the benzimidazoles as a hit cluster and showed mebendazole's activity across 80% of colon cancer lines in the NCI-60 panel, with kinase interactions that albendazole lacked. It broadened the mebendazole-cancer case beyond lung and brain. Study type: cell-line screen and bioinformatics (preclinical). N: two established colon cancer lines screened against 1,600 compounds at 10 micromolar, plus three further colon lines and three non-malignant models. Country: Sweden (Uppsala University). Funder/conflicts: not stated in the abstract; full text paywalled/not read. Product: laboratory compounds. Comparator: non-malignant cell models; albendazole as a comparator benzimidazole. Also filed as MBB-45 (claims C6, C7).